Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based
Benjamin P Levy1, Marc D Chioda2, Dana Herndon2
1Mount Sinai Health Systems, New York, New York, USA; Pfizer Oncology, New York, New York, USA; Cone Health Cancer Center, Greensboro, North Carolina, USA; Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, USA; Chao Family Comprehensive Cancer Center, University of California at Irvine School of Medicine, Orange, California, USA; US Oncology Research, Ocala, Florida, USA; Carolinas HealthCare System, Charlotte, North Carolina, USA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Colorado Cancer Center, Aurora, Colorado, USA belevy@chpnet.org.
Abstract:
The recent discovery of relevant biomarkers has reshaped our approach to therapy selection for patients with non-small cell lung cancer. The unprecedented outcomes demonstrated with tyrosine kinase inhibitors in molecularly defined cohorts of patients has underscored the importance of genetic profiling in this disease. Despite published guidelines on biomarker testing, successful tumor genotyping faces significant hurdles at both academic and community-based practices. Oncologists are now faced with interpreting large-scale genomic data from multiple tumor types, possibly making it difficult to stay current with practice standards in lung cancer. In addition, physicians' lack of time, resources, and face-to-face opportunities can interfere with the multidisciplinary approach that is essential to delivery of care. Finally, several challenges exist in optimizing the amount and quality of tissue for molecular testing. Recognizing the importance of biomarker testing, a series of advisory boards were recently convened to address these hurdles and clarify best practices. We reviewed these challenges and established recommendations to help optimize tissue acquisition, processing, and testing within the framework of a multidisciplinary approach.
Insights
Biomarker testing is crucial for non-small cell lung cancer (NSCLC) therapy selection. This study addresses challenges in tumor genotyping and tissue optimization to improve molecular testing practices for better patient care.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genomics
Background:
- Biomarker discovery has transformed non-small cell lung cancer (NSCLC) treatment selection.
- Tyrosine kinase inhibitors show significant efficacy in molecularly defined NSCLC patient cohorts.
- Genetic profiling is essential for personalized NSCLC therapy.
Purpose of the Study:
- To identify and address practical challenges in tumor genotyping for NSCLC.
- To clarify best practices for molecular testing in academic and community settings.
- To optimize tissue acquisition, processing, and testing for NSCLC biomarker analysis.
Main Methods:
- Review of challenges in implementing biomarker testing guidelines for NSCLC.
- Analysis of factors hindering successful tumor genotyping (e.g., data interpretation, resources).
- Convening of advisory boards to discuss and establish recommendations for best practices.
Main Results:
- Significant hurdles exist in performing comprehensive tumor genotyping in routine clinical practice.
- Physician-related factors (time, resources, multidisciplinary collaboration) impede optimal testing.
- Tissue quality and quantity present challenges for accurate molecular testing.
Conclusions:
- Addressing practical challenges is vital for widespread adoption of biomarker testing in NSCLC.
- Recommendations were developed to optimize tissue handling and molecular testing processes.
- A multidisciplinary approach is essential for integrating molecular profiling into NSCLC patient care.
